Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, double-dummy, active (formoterol 12 microg b.i.d. [twice daily]) and placebo controlled, multi-center, 5 period crossover study to assess the bronchodilatory efficacy and safety of single doses of indacaterol 150 microg, 300 microg and 600 microg delivered via single dose dry powder inhaler versus placebo in patients with moderate to severe COPD [chronic obstructive pulmonary disease].

Trial Profile

A randomized, double-blind, double-dummy, active (formoterol 12 microg b.i.d. [twice daily]) and placebo controlled, multi-center, 5 period crossover study to assess the bronchodilatory efficacy and safety of single doses of indacaterol 150 microg, 300 microg and 600 microg delivered via single dose dry powder inhaler versus placebo in patients with moderate to severe COPD [chronic obstructive pulmonary disease].

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Nov 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 24 Oct 2011 Actual end date (January 2007) added as reported by ClinicalTrials.gov.
    • 07 Oct 2008 Results were reported at the Annual Congress of the European Respiratory Society.
    • 07 Oct 2008 Secondary endpoint 'Forced vital capacity' has been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top